GSK’s experimental HSV vaccine fails to meet main goal in trial

(Reuters) – British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D’Souza)